We pioneering the development of innovative therapeutics by combining approved generic drugs for new indications, routes of administration, and advanced formulations. Our mission is to rapidly address urgent unmet medical needs with proven safety and accelerated clinical timelines.
We harness the power of approved generics, designing novel combinations and formulations to unlock new therapeutic potential and improve patient outcomes.
By repurposing and reformulating existing drugs, we deliver treatments for conditions where current options are limited or non-existent.
Leveraging established safety profiles, we streamline regulatory pathways and clinical development, enabling faster access for patients in need.
• Development of innovative drug combinations and novel formulations targeting heart conditions such as hypertension, heart failure, and cardiomyopathies.
• Emphasis on therapies for high triglycerides and mixed hyperlipidemia, areas with significant unmet need.
• Utilization of fixed-dose combinations to improve adherence and outcomes in cardiovascular disease management.
• Dedicated pipeline for nephrology, addressing chronic kidney disease, acute kidney injury, and related conditions.
• Focus on novel combinations and new routes of administration for improved efficacy and patient convenience.
• Targeting high-risk patients with comorbid cardiovascular and renal disease, but with distinct, specialized therapies for each indication.
• Precision Therapeutics: Developing targeted drug combinations and advanced formulations for orphan and ultra-rare conditions with high unmet medical need.
• Accelerated Pathways: Leveraging regulatory incentives and established safety profiles of generics to rapidly advance treatments for rare genetic, metabolic, and immunological disorders.
• Patient-Centric Approach: Collaborating with patient advocacy groups and rare disease networks to ensure access and address the unique challenges of small patient populations.
• Innovative Neurotherapeutics: Creating new indications and delivery methods for approved drugs to address neurodegenerative, neuroinflammatory, and neuropsychiatric conditions.
• Focus Areas: Targeting diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, and rare neurological syndromes with novel fixed-dose combinations and reformulations.
• Improved Outcomes: Enhancing efficacy, safety, and patient adherence through optimized dosing and administration tailored to neurological patient needs.
We build on the robust safety and efficacy of generics, reducing risk and accelerating innovation.
Our therapies are designed for those with the greatest unmet needs, including rare and complex diseases.
Our focus aligns with the hottest therapeutic areas attracting global investment and partnership interest.
ArbusPharma is advancing a dynamic pipeline and forging strategic partnerships to bring transformative therapies to patients worldwide. Discover how we are redefining the future of medicine-today.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.